Home › Research › Tau biomarkers
Plasma Aβ42/Aβ40 and p-tau181 Predict Long-Term Clinical Progression in a Cohort with Amnestic Mild Cognitive Impairment
Xiao Z, Wu W, Ma X, Liang X, Lu J, Zheng L, Ding S, Lei Q et al.. Clinical chemistry, 2022-12-01
Topic: Amyloid, tau and blood-test diagnosis
Background Previous studies reported the value of blood-based biomarkers in predicting Alzheimer disease (AD) progression among individuals with different disease stages. However, evidence regarding the value of these markers in those with amnestic mild cognitive impairment (aMCI) is insufficient. Methods A cohort with 251 aMCI individuals were followed for up to 8 years.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Xiao, Z., Wu, W., Ma, X., Liang, X., Lu, J., Zheng, L., et al. (2022). Plasma Aβ42/Aβ40 and p-tau181 Predict Long-Term Clinical Progression in a Cohort with Amnestic Mild Cognitive Impairment. Clinical chemistry. https://doi.org/10.1093/clinchem/hvac149
Vancouver
Xiao Z, Wu W, Ma X, Liang X, Lu J, Zheng L, et al. Plasma Aβ42/Aβ40 and p-tau181 Predict Long-Term Clinical Progression in a Cohort with Amnestic Mild Cognitive Impairment. Clinical chemistry. 2022. doi:10.1093/clinchem/hvac149. PMID: 36208187.
BibTeX
@article{xiao2022-36208187,
author = {Xiao, Z. and Wu, W. and Ma, X. and Liang, X. and Lu, J. and Zheng, L. and Ding, S. and Lei, Q. and others},
title = {{Plasma Aβ42/Aβ40 and p-tau181 Predict Long-Term Clinical Progression in a Cohort with Amnestic Mild Cognitive Impairment}},
journal = {Clinical chemistry},
year = {2022},
doi = {10.1093/clinchem/hvac149},
pmid = {36208187},
url = {https://doi.org/10.1093/clinchem/hvac149}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- However, evidence regarding the value of these markers in those with amnestic mild cognitive impairment (aMCI) is insufficient.
- Methods A cohort with 251 aMCI individuals were followed for up to 8 years.
- Baseline blood biomarkers were measured on a single-molecule array platform.
- Multipoint clinical diagnosis and domain-specific cognitive functions were assessed to investigate the longitudinal relationship between blood biomarkers and clinical AD progression.
Why it matters
In 251 people with amnestic mild cognitive impairment followed up to 8 years, baseline blood Aβ42/Aβ40 and p-tau181 predicted long-term clinical progression to Alzheimer's disease. This is a prediction study, so it does not show that any treatment, cure or prevention works.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designlongitudinal study
- Effect sizeAUC = 0.825
- Evidence strengthModerate
How this study scored 52/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Clinical chemistry) |
| Journal's citation record | 3 / 4 | Clinical Chemistry: journal h-index 323 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 28 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.7 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 3 / 6 | Cited 3.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 21 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Qianhua Zhao: h-index 41 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Fudan University: institution h-index 954 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36208187) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.
Related studies in Tau biomarkers
Also tagged “phosphorylated”
733 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 733 tagged studies.